Journal of Geriatric Psychiatry and Neurology

Size: px
Start display at page:

Download "Journal of Geriatric Psychiatry and Neurology"

Transcription

1 Journal of Geriatric Psychiatry and Neurology Are Parkinson's Disease with dementia and Dementia with lewy Bodies the Same Entity? Dag Aarsland, C. G. Ballard and Glenda Halliday J Geriatr Psychiatry Neurol : 137 DOI: / The online version of this article can be found at: Published by: Additional services and information for Journal of Geriatric Psychiatry and Neurology can be found at: Alerts: Subscriptions: Reprints: Permissions: Citations: >> Version of Record - Aug 5, 2004 What is This? Downloaded from jgp.sagepub.com at PENNSYLVANIA STATE UNIV on March 4, 2014

2 Are Parkinson s Disease With Dementia and Dementia With Lewy Bodies the Same Entity? Dag Aarsland, MD, PhD, C. G. Ballard, MD, MRCPsych, and Glenda Halliday, PhD ABSTRACT The diagnosis of Parkinson's disease with dementia (PDD) or dementia with Lewy bodies (DLB) is based on an arbitary distinction between the time of onset of motor and cognitive symptoms. These syndromes share many neurobiological similarities, but there are also differences. Deposition of beta-amyloid protein is more marked and more closely related to cognitive impairment in DLB than PDD, possibly contributing to dementia at onset. The relatively more severe executive impairment in DLB than PDD may relate to the loss of frontohippocampal projections in DLB. Visual hallucinations and delusions associate with more abundant Lewy body pathology in temporal cortex in DLB. The differential involvement of pathology in the striatum may account for the differences in parkinsonism. Longitudinal studies with neuropathological and neurochemical evaluations will be essential to enable more robust comparisons and determine pathological substrates contributing to the differences in cognitive, motor, and psychiatric symptoms. (J Geriatr Psychiatry Neurol 2004; 17: ) Keywords: cognition; dementia; Lewy bodies; neurochemistry; neuropathology; parkinsonism Dementias associated with cortical Lewy bodies are traditionally classified as dementia with Lewy bodies (DLB), characterized by parkinsonism, visual hallucinations and cognitive fluctuations, 1 or Parkinson s disease with dementia (PDD). Overall, DLB accounts for about 20% of late-onset dementia cases, 1 and dementia develops in the majority of cases with a diagnosis of PD. 2 As outlined below, there are clinical and neurobiological similarities between DLB and PDD patients. The distinction between the conditions as operationally defined within the standardized clinical criteria depends entirely on the duration of parkinsonism prior to dementia. The consensus criteria for a clinical diagnosis of DLB state that a diagnosis cannot be made if parkinsonian symptoms developed more than 1 year before the onset From the Psychiatric Clinic, Rogaland Central Hospital, Stavanger, Norway (Dr Aarsland); Institute of Psychiatry, King s College London, United Kingdom (Dr. Ballard); and Prince of Wales Medical Research Institute and the University of New South Wales, Sydney, Australia (Dr Halliday). Address correspondence to: Dag Aarsland, MD, PhD, Centre for Neuro and Geriatric Psychiatric Research, Psychiatric Clinic, Rogaland Central Hospital, PO Box 1163, Hillevaag, 4095 Stavanger, Norway; e- mail: daa@sir.no. DOI: / of dementia (although proposed recent changes to the criteria may alter this to making the diagnosis according to whether parkinsonism or cognitive impairment arises first). This raises several key conceptual questions; for example, are these conditions distinct or part of the same spectrum? If they are distinct conditions, is an arbitrary cutoff (either 1 year or which symptom presents first) a meaningful distinction between clinical entities with different clinical presentations? Addressing these issues is critical to taking forward our understanding of this spectrum of conditions, establishing biological markers, determining prognostic indicators, and, most important, designing appropriate intervention studies and developing treatment paradigms across the dementias associated with cortical Lewy bodies. In the current article, key issues pertaining to DLB and PDD are reviewed, and the similarities and differences in the clinical profile (cognitive deficits, neuropsychiatric symptoms, and parkinsonism), imaging, genetic predisposition, neurochemistry, and neuropathology are discussed to enable some conclusions about the relationship of the 2 conditions and to offer some suggestions for critical future research. Direct comparative studies of patients with PDD and DLB are necessary to explore the relationship between these 2 syndromes. We searched the MEDLINE using Parkinson* disease and dementia 2004 Sage Publications 137

3 138 Journal of Geriatric Psychiatry and Neurology / Vol. 17, No. 3, September 2004 with Lewy bodies as search (title) words, as well as searching book chapters and abstracts that were available to us. Methodological Issues Direct comparative studies are the preferred choice to explore the relationship between DLB and PDD, but several methodological issues need to be borne in mind when considering such studies. Critical issues include the selection of subjects (ie, whether community based or hospital based); the severity of dementia; whether subjects were matched for severity of dementia, sample size, sensitivity, and other psychometric properties of the tests used to characterize the patients; and diagnostic criteria and methods of diagnosis (eg, diagnosis based on autopsy, prospective clinical assessment, or retrospective chart review). Many studies comparing neuropathology or chemistry in PD and DLB did not specify whether PD patients had dementia. Because these 2 groups differ markedly in this regard, the interpretation of results from most of these studies is difficult. COMPARATIVE STUDIES OF STRUCTURAL NEUROPATHOLOGY IN PDD AND DLB Atrophy and Cortical Cell Loss Although DLB and PDD cannot be differentiated based on the pattern of brain atrophy, 3 both have limited atrophy compared with other dementia syndromes. There is no substantial subcortical atrophy in pathologically confirmed cases, 4-7 although a small reduction in the volume of the putamen has been documented in vivo. 8 Mild frontal lobe atrophy and medial temporal lobe atrophy are consistent features. 3,4,6 Temporal lobe and occipital atrophy has been documented in some clinical cohorts, 3,9 but these regions are spared in pathologically confirmed cases, 4,6 unless they also have Alzheimer s disease. 5 In both DLB and PDD, there is limited cortical cell loss, even in frontal regions Medial temporal lobe structures are abnormal in both DLB and PDD, although hippocampal cell loss may differentiate DLB from PDD. In both conditions, however, the severity of hippocampal atrophy is less marked than that seen in Alzheimer s disease. Both Lewy body disorders have significant but similar atrophy and pathology in the amygdala. 6 In contrast, hippocampal pyramidal neurons innervating the frontal cortex selectively degenerate in DLB. 13 Amount of Lewy Body Pathology In many cortical regions, the amount of Lewy body pathology does not differentiate DLB from PDD or PD, 14 although more temporal lobe Lewy bodies occur in DLB. The lack of an association between the amount of cortical Lewy body pathology and the timing of dementia in Lewy body diseases is disconcerting but well documented and suggests that Lewy bodies are not the only pathology contributing to these dementia syndromes. However, subtle differences in the type and severity of pathology between DLB and PDD influence clinical phenotype. The increase in temporal lobe Lewy bodies in DLB correlates with the early occurrence of the characteristic well-formed visual hallucinations rather than dementia duration or severity. In contrast, increasing Lewy body densities in limbic and frontal cortices in PDD correlate with the severity of dementia. 19,20 This dichotomy of regional Lewy body pathology suggests that the disease processes driving DLB and PDD differ. Other Contributing Pathologies Most cases of DLB can be differentiated from those with PDD by their substantial deposition of cortical amyloidbeta (Aβ), even in the absence of significant neurofibrillary tangle formation. 14,21 This further substantiates different disease processes between DLB and PDD, with the density of Aβ-positive plaques in DLB equivalent to that found in Alzheimer s disease. Although the amount of Aβ deposition and cortical Lewy bodies correlates with dementia severity in DLB, this does not seem to be the case in PDD. In a prospective clinicopathologic study of population-based samples of patients with dementia and with PD, Lewy body formation but not neuritic plaque pathology contributed to dementia severity in PD, whereas both pathologies contributed to dementia severity in DLB cases. 14 Thus, the amount of Lewy body formation does not relate to whether dementia occurs early (ie, DLB) or late (ie, PDD) in the disease course but correlates with the severity of dementia in PDD. Similar findings have been reported in other studies, 19,20 although in some studies, Alzheimer-type pathology was reported to be significantly associated with dementia in PD. 22 COMPARATIVE STUDIES OF NEUROCHEMICAL CHANGES IN PDD AND DLB Most neurochemical studies of DLB and PD have focused on the cholinergic and dopaminergic neurotransmitter systems, which may influence a range of key clinical symptoms such as cognition, attentional fluctuations, hallucinations, delusions, and parkinsonism. Dopaminergic Deficits Caudate nucleus dopamine loss is pronounced in both DLB and PD, 23 with subtle differences in the symmetry and rostrocaudal gradient in DLB and PDD, consistent with the subtle differences in the presentation of parkinsonian symptoms (see below). However, direct comparison of the degree of cell loss in the dopaminergic substantia nigra in PD, PDD, and DLB suggests a similar pattern of cell loss in the dopaminergic substantia nigra. The degree of nigral loss is >60% in all subjects and correlates with disease duration, which is longer in

4 Parkinson s Disease and Dementia / Aarsland et al 139 PD and PDD than in DLB. 26 Greater loss of striatal dopamine is therefore observed in PD compared with DLB, 23 with more abundant residual neuritic pathology observed in DLB than in PD. 27,28 In PD but not in DLB, there is a compensatory increase in striatal D2 receptors and dopamine turnover, 23 with PDD patients having intermediate D2 binding between DLB and PD. 29 The consistent dopaminergic deficit is being translated into a useful clinical imaging tool for differentiating DLB from Alzheimer s disease and other dementia syndromes. 24,30 Cholinergic Deficits Neurochemical studies consistently find marked cortical cholinergic deficits in both PDD and DLB, more marked than in PD cases without dementia, 31,32 suggesting that the amount of cholinergic cell loss in the basal forebrain cholinergic neurons supplying the majority of cortical acetylcholine is similar in DLB 33 and PDD. 34 However, differential involvement of the cholinergic system in DLB and PD has also been reported. Cholinergic markers are reduced in the striatum in patients with DLB but not in those with PD. 35,36 Furthermore, in selected thalamic nuclei, marked reductions were found in PDD and in DLB patients with but not without parkinsonism. 32 In DLB but not in PDD, there is a correlation between visual hallucinations and cholinergic deficits in the temporal cortex. 37 The impact on cortical cholinergic receptors is similar in PDD and DLB, with increased muscarinic binding 38 and a considerable reduction in nicotinic binding, although in the insular cortex the reductions were more marked in PDD than in DLB. 39 Further studies indicate a possible association between impaired consciousness and upregulation of nicotinic α4β2 nicotinic receptors in the temporal cortex. In a study comparing muscarinic receptor binding within the striatum in DLB and PD patients, M1 receptors were significantly reduced in DLB but not in PD patients. However, the 3 PD patients with dementia had binding levels intermediate between PD and DLB. 29 In both DLB and PD, there is a similar reduction in striatal nicotinic binding consistent with these receptors being located on dopaminergic terminals. 35 For a more comprehensive review of cholinergic changes in DLB and PDD, see references in this issue. GENETICS IN PDD AND DLB So far, there are insufficient data to make meaningful conclusions regarding the similarities and differences in the genetic factors predisposing to PDD and DLB. Causal Genes Recent studies have identified several loci involved in the development of PD. In rare families, point mutations in the alpha-synuclein gene (SNCA) give rise to autosomal dominant PD. 40 Although parkinsonism is usually the presenting feature in familial PD, in some individuals dementia is the presenting feature, and these cases show extensive cortical Lewy body pathology. 41 Thus, at least in some cases, PD and DLB are genetically closely related. In addition, as many as 5% of cases of earlyonset (<60 years) PD and PDD appear to be due to triplication or duplication of SNCA. 42 Although there is some evidence indicating that genetic factors contribute to DLB, 43,44 the genes predisposing to PD have not yet been systematically investigated in DLB. Modifying Genes The apolipoprotein ε4 allele has a higher frequency in DLB than in age-matched controls 45 and is associated with a more rapid progression of cognitive impairment in affected individuals. Similarly, a possible association between the apolipoprotein ε4 allele and dementia in PD has been reported, 46 although other studies did not find such an association. COMPARATIVE STUDIES OF CLINICAL FEATURES IN PDD AND DLB Cognitive Deficits The cognitive profile of both PDD and DLB has been characterized as featuring visuospatial, attentional, and executive impairment with relatively less memory impairment. 1,47 This is based on studies comparing DLB and PDD patients with patients with Alzheimer s disease. The overall profile of cognitive deficits is quite similar in the 2 syndromes (details of studies in Table 1), with both PDD and DLB patients exhibiting significantly more marked executive and less severe memory deficits than did those with Alzheimer s disease. Interestingly, fluctuating attention, a key feature of DLB, was found in both DLB and PDD patients but not in patients with Alzheimer s disease or PD without dementia, and less marked fluctuation of attention was also found in DLB patients without parkinsonism. 48 An additional study comparing pentagon copying in patients with DLB and PDD suggested a similar severity of impairment in the 2 conditions and a pattern of errors indicating executive dysfunction. 49 A further study, although suggesting marked executive dysfunction in both PDD and DLB, showed that in the context of mild dementia, patients with DLB had a significantly lower score on the Dementia Rating Scale Conceptualization subscale than did PD patients, suggesting that executive impairment is more pronounced in DLB than in PD patients with mild dementia. Overall, however, the profile of cognitive impairments in DLB and PDD appears to be similar and distinct from Alzheimer s disease but with some subtle differences, including more marked executive dysfunction in DLB.

5 140 Journal of Geriatric Psychiatry and Neurology / Vol. 17, No. 3, September 2004 Psychiatric Symptoms Psychiatric symptoms are common in all dementia syndromes, but a characteristic psychiatric profile has been reported in patients with DLB and PDD (Table 2). Visual hallucinations and delusions are much more common in DLB than in Alzheimer s disease, occurring in 60% to 70% of patients with DLB, 50,51 whereas in PDD, hallucinations (45%-50%) but not delusions (15%-24%) were more common than in Alzheimer s disease. 51,52 Another distinguishing feature of these syndromes is the high frequency of REM sleep disorders, which are also much more common in DLB and PDD than in other dementias (see Boeve, this issue). 53 Other symptoms commonly reported, such as depression, apathy, and anxiety, are common in other dementias, although several studies suggest a higher frequency of depression in DLB, 50,51 consistent with the high frequency of depression in PD. 54 Comparisons of the phenomenology of psychotic symptoms in DLB and PDD show that the content of the hallucinations and delusions was indistinguishable. 51,52 However, the frequency of hallucinations 51,52 and delusions 52 was significantly higher in DLB patients than in PDD patients. Parkinsonism It has frequently been suggested, based largely on anecdote, that parkinsonism is less severe in DLB than in PD. However, comparative studies have usually not supported this view, finding similar or even more severe symptoms in DLB than in PD (Table 3). A similar profile of parkinsonism has also been reported, 55 although in one study DLB patients had more symmetrical parkinsonism and relatively higher rigidity and lower resting tremor scores than did PD patients. 56 Importantly, these studies usually included subjects with and without dementia. In the most detailed comparative study of parkinsonism to date, Burn et al found that DLB patients had less severe parkinsonism than did PDD patients but a similar severity of motor deficits to PD patients without dementia. 57 Postural instability and gait difficulties, predominantly mediated by nondopaminergic deficits, were more pronounced in DLB and PDD patients than in PD patients without dementia, whereas the opposite was found for tremor. Although there are no direct comparative studies, the rate of progression of rating scales of parkinsonism appears to be about 9% per annum in DLB and PD. 58,59 Overall, therefore, severity of parkinsonism is similar in DLB and PD and progresses at the same rate, although there appears to be relatively more nondopaminergic symptoms and less asymmetry in DLB, consistent with neurochemical findings. Treatment Studies Frequently, DLB patients experience severe sensitivity reactions in response to neuroleptic drugs (NSR), 60 and preliminary evidence suggests similar reactions in a considerable proportion of PDD patients, although occurring less commonly than in DLB patients. 61 The symptoms of severe NSR experienced by the respective groups of patients are very similar, although it appears that PDD patients are less likely to die within a few months of neuroleptic exposure. Two randomized placebo-controlled studies support the use of clozapine for PD patients with psychosis (with no or mild dementia), but undertaking such trials in DLB is problematic because of the high frequency of severe NSR and the high related mortality rates. Recent reports of higher mortality rates and risk of cerebrovascular incidents in elderly patients with dementia associated with risperidone and olanzapine underline the potential high risk of these agents. Favorable symptomatic improvement is seen in both DLB and PDD following cholinesterase inhibitor therapy (see articles in this issue). We are aware of only one open-label study comparing the treatment effects in PDD and DLB. Minett et al 62 showed a similar improvement on cognition and psychiatric symptoms on donepezil in DLB and PDD patients and no change in parkinsonism in both groups, although PDD patients showed a greater worsening of psychiatric symptoms after withdrawal of the drug. Unfortunately, there are no systematic reports of the response to levodopa treatment in DLB patients, and no published comparisons exist. Theoretically, the high proportion of DLB patients with predominantly nondopaminergic motor deficits suggests that such therapy would be less effective in DLB patients than in PD patients. Preliminary evidence from ongoing studies supports this hypothesis. 63 DISCUSSION Summary of Major Findings Although methodological shortcomings of comparative studies of DLB and PDD make interpretation difficult, there is evidence of considerable overlap in the clinical, neurochemical, and pathological features of DLB and PDD. Both have parkinsonism, similar cognitive deficits, similar patterns of atrophy, similar amounts of Lewy body pathology, and similar substantial cholinergic and dopaminergic deficits that appear amenable to similar treatments. However, although there are many similarities in the type and frequency of clinical features diagnostic for DLB and PDD, the severity of executive dysfunction, frequency of visual hallucinations and delusions, and relative predominance of postural instability/gait disorders are significantly greater in DLB than in PDD. Subtle neurochemical and pathological differences are likely to subserve these differences. Executive dysfunction may relate to the loss of the hippocampal projection to the frontal lobe in DLB but not in PD, and more severe Lewy body pathology may relate to the high-

6 Table 1. Comparative Studies of Cognitive Impairment in Parkinson s Disease (PD) and Dementia With Lewy Bodies (DLB) PD DLB Severity Severity of Cognitive of Cognitive Study N Age Impairment a N Age Impairment a Cognitive Test Finding Aarsland et al b and b and DRS Similar but more executive imp in DLB; mild Noe et al b b BSRT, BVRT, VF, BNT, selected tests from WAIS-R, No difference DRS, BDAE, attention, RDT Horimoto et al 68 (clinicopathologic study) c 5 b,c c 9 c MMSE No significant difference Downes et al d * d WAIS-R, WMS-R, WRMT, VF, Stroop More executive impairment in DLB Gnanalingham et al b * b Digit span, VF, Clock draw Nelson Card Test, Worse in DLB: attention, executive functions motor sequencing Cahn-Weiner et al e e Clock draw f Overall score similar; 1/9 subscores differed: more conceptual errors in DLB Ballard et al CDR No difference Cormack et al b b Clock draw g No difference Note: DRS, Dementia Rating Scale; BSRT, Buschke Selective Reminding Test; BVRT, Benton Visual Retention Test; VF, Verbal Fluency Test; BNT, Boston Naming Test; WAIS-R, Wechsler Adult Intelligence Scale Revised; BDAE, Boston Diagnostic Aphasia Examination; RDT, Rosen Drawing Test; MMSE, Mini Mental State Examination; WMS-R, Wechsler Memory Scale Revised; WRMT, Warrington Recognition Memory Test; CDR, Cognitive Drug Research computerized battery (tests of simple, choice, and cognitive reaction times). a. Not demented. b. The measure of the severity of cognitive impairment was the MMSE. c. For this study, the age is the age at onset of dementia and the severity of cognitive impairment is the final MMSE score. d. The measure of the severity of cognitive impairment was the IQ test. e. The measure of the severity of cognitive impairment was the DRS. f. The scoring system of the clock drawing was from Rouleau 73 g. The scoring system of the clock drawing was from Bourke 74 *modified Stern et al 75 Parkinson s Disease and Dementia / Aarsland et al 141

7 142 Journal of Geriatric Psychiatry and Neurology / Vol. 17, No. 3, September 2004 Table 2. Comparative Studies of Psychiatric Symptoms in Parkinson s Disease With Dementia (PDD) and Dementia With Lewy Bodies (DLB) PDD DLB and course. Although the current evidence demonstrates remarkable similarities between DLB and PDD, there are also both subtle and marked differences. The available evidence suggests that the heterogeneity within the 2 syndromes may be greater than the differences between them. For example, some patients who develop parkinsonism will develop dementia within a year and be classified as DLB, others will develop a dementia syndrome within a 5- to 10-year period and thus be classified as PDD patients, whereas some patients with PD will remain cognitively intact for decades. Current diagnostic classification of patients with parkinsonian dementias is based only on the timing of motor and cognitive symptoms with some data supporting this distinction (see above). 17 We recommend further research to provide more empirical evidence for the classification. There is significant biological overlap between DLB and PDD, and it will be important to determine the reasons for such overlap, as well as the neurobiological dif- Visual Visual Hallucin- Hallucin- Study Measure N Age MMSE Delusions ations Depression N Age MMSE Delusions ations Depression Aarsland et al 52 NPI/CUSPAD a a Noe et al 67 Clinical b b Klatka et al 51 (retrospective study) Clinical 26 c 75 d ND d ND Note: Numbers represent percentage of patients with symptom present. MMSE, Mini Mental State Examination; NPI, Neuropsychiatric Inventory; CUSPAD, Columbia University Scale for Psychopathology in Alzheimer s Disease; ND, no data. a. Major and minor depression combined. b. Modified MMSE. c. There were 8 patients with dementia. d. This is the age at death. Table 3. Comparative Studies of Parkinsonism in Parkinson s Disease (PD) and Dementia With Lewy Bodies (DLB) PD DLB UPDRS, Study N Age MMSE Motor N Age MMSE Score Profile Burn and McKeith , significant PIGD more common in DLB and PD with dementia than in PD Noe et al a a 13, NS Similar Fernandez et al No data Gnanalingham et al DLB: higher rigidity, reduced tapping speed; PD: more tremor dominant, more asymmetric PD Aarsland et al b b No difference Note: MMSE, Mini Mental State Examination; PIGD, postural instability-gait difficulty motor phenotype; PDRS, Unified Parkinson s Disease Rating Scale; NS, not significant. a. Modified MMSE. b. Modified UPDRS. See Ballard C, McKeith I, Burn D, et al. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand 1997; 96: er frequency of psychiatric features in DLB. The differential pattern of parkinsonian features in PD and DLB is in accordance with the differential striatal changes, with changes in PDD patients being intermediate between those found in DLB and PD patients. Of course, the most obvious difference is the early onset of dementia in DLB compared to that of PDD. The explanation for this relationship may be the pathological feature that occurs in DLB and not in PDD, the presence of substantial cortical Aβ protein deposition. Thus, DLB is similar to Alzheimer s disease in that it has 2 major pathologies, cortical Aβ and Lewy bodies in DLB versus cortical Aβ and neurofibrillary tangles in Alzheimer s disease, whereas PDD has mainly Lewy body pathology and a late onset of dementia. Nosological Aspects A classical nosological definition of a disease includes common etiology, pathophysiology, clinical presentation,

8 Parkinson s Disease and Dementia / Aarsland et al 143 ferences. The occurrence of cortical Aβ plaque pathology adds further complexity to the interpretation. Two recent studies 64,65 indicate that DLB patients with marked neurofibrillary tangle pathology (ie, coexisting Alzheimer s disease) are less likely to present with the typical features of DLB (including impaired consciousness and parkinsonism). There is considerable debate as to the classification of patients with coexisting Alzheimer s disease and DLB (3 substantive pathologies), as the DLB syndrome appears to be less distinct in these cases. There are 4 possible models that could be used to classify DLB and PDD. (1) They could be considered as distinct conditions. (2) They could be considered as part of a spectrum of dementia related to cortical Lewy body disease. (3) Both DLB with parkinsonism and PDD could be considered as a distinct condition but separate from DLB without parkinsonism and PD without dementia. (4) They could be considered as part of a spectrum of Lewy body and Alzheimer-type pathology. The commonality of the presenting symptoms, treatment response, and many neuropathological/neurochemical substrates would seem to best support a spectrum model, although the additional cortical Aβ deposition in DLB suggests important differences subserving dementia at onset. The paucity of direct comparisons, however, makes conclusions speculative, and further comparative studies are a high priority. Longitudinal studies with neuropathological and neurochemical evaluations are essential to enable more robust comparisons and to determine the impact on presentation of the individual pathological substrates that may contribute to cognitive, motor, and psychiatric symptoms. References 1. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60: Burton EJ, McKeith IG, Burn DJ, Williams ED, O Brien JT. Cerebral atrophy in Parkinson s disease with and without dementia: a comparison with Alzheimer s disease, dementia with Lewy bodies and controls. Brain 2004; 127(pt 4): Double KL, Halliday GM, McRitchie DA, Reid WG, Hely MA, Morris JG. Regional brain atrophy in idiopathic Parkinson s disease and diffuse Lewy body disease. Dementia 1996; 7: Harvey GT, Hughes J, McKeith IG, et al. Magnetic resonance imaging differences between dementia with Lewy bodies and Alzheimer s disease: a pilot study. Psychol Med 1999; 29: Cordato NJ, Halliday GM, Harding AJ, Hely MA, Morris JG. Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann Neurol 2000; 47: Barber R, McKeith I, Ballard C, O Brien J. Volumetric MRI study of the caudate nucleus in patients with dementia with Lewy bodies, Alzheimer s disease, and vascular dementia. J Neurol Neurosurg Psychiatry 2002; 72: Cousins DA, Burton EJ, Burn D, Gholkar A, McKeith IG, O Brien JT. Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer s disease: an MRI study. Neurology 2003; 61: Barber R, McKeith IG, Ballard C, Gholkar A, O Brien JT. A comparison of medial and lateral temporal lobe atrophy in dementia with Lewy bodies and Alzheimer s disease: magnetic resonance imaging volumetric study. Dement Geriatr Cogn Disord 2001; 12: Gomez-Isla T, Growdon WB, McNamara M, et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999; 53: Broe M, Shepherd CE, Milward EA, Halliday GM. Relationship between DNA fragmentation, morphological changes and neuronal loss in Alzheimer s disease and dementia with Lewy bodies. Acta Neuropathol (Berl) 2001; 101: Shepherd CE, McCann H, Thiel E, Halliday GM. Neurofilament-immunoreactive neurons in Alzheimer s disease and dementia with Lewy bodies. Neurobiol Dis 2002; 9: Harding AJ, Lakay B, Halliday GM. Selective hippocampal neuron loss in dementia with Lewy bodies. Ann Neurol 2002; 51: Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol (Berl) 2001; 102: Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body cortical involvement may not always predict dementia in Parkinson s disease. J Neurol Neurosurg Psychiatry 2003; 74: Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59: Richard IH, Papka M, Rubio A, Kurlan R. Parkinson s disease and dementia with Lewy bodies: one disease or two? Mov Disord 2002; 17: Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: Samuel W, Galasko D, Masliah E, Hansen LA. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer s disease. J Neuropathol Exp Neurol 1996; 55: Kovari E, Gold G, Herrmann FR, et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson s disease. Acta Neuropathol (Berl) 2003; 106: Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA. Prevalence of amyloid-beta deposition in the cerebral cortex in Parkinson s disease. Mov Disord 2003; 18: Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson s disease. J Neural Transm 2002; 109: Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer s and Parkinson s diseases: rostrocaudal distribution. Brain 1999; 122(pt 8): O Brien JT, Colloby SJ, Aarsland D, et al. Dopamine transporter loss visualised with PF-CIT SPECT in dementia with Lewy bodies. Arch Neurol In press. 25. Ransmayrl G, Seppi K, Donnemiller E, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson s disease. Eur J Nucl Med 2001; 28:

9 144 Journal of Geriatric Psychiatry and Neurology / Vol. 17, No. 3, September Halliday GM, McRitchie DA, Cartwright H, Pamphlett R, Hely MA, Morris JG. Midbrain neuropathology in idiopathic Parkinson s disease and diffuse Lewy body disease. J Clin Neurosci 1996; 3: Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002; 52: Duda JE. Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord 2004; 17(suppl 1): Piggott MA, Owens J, O Brien J, et al. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson s disease and Alzheimer s disease. J Chem Neuroanat 2003; 25: Suzuki M, Desmond TJ, Albin RL, Frey KA. Striatal monoaminergic terminals in Lewy body and Alzheimer s dementias. Ann Neurol 2002; 51: Tiraboschi R, Hansen LA, Alford M, et al. Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000; 54: Ziabreva I, Ballard CG, Aarsland D, Larsen JP, Perry EK. Cortical and thalamic cholinergic activity in Lewy body disease in relation to dementia and parkinsonism. Paper presented at: 8th International Congress of Parkinson s Disease and Movement Disorders; June 13-17, 2004; Rome, Italy. 33. Lippa CF, Smith TW, Perry E. Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology. J Neural Transm 1999; 106: Perry EK, Curtis M, Dick DJ, et al. Cholinergic correlates of cognitive impairment in Parkinson s disease: comparisons with Alzheimer s disease. J Neurol Neurosurg Psychiatry 1985; 48: Court JA, Piggott MA, Lloyd S, et al. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson s disease and Alzheimer s disease and in relation to neuroleptic medication. Neuroscience 2000; 98: Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer s and Parkinson s diseases. J Neurochem 1992; 58: Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000; 48: Perry EK, Irving D, Kerwin JM, et al. Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993; 7: Pimlott SL, Piggott M, Owens J, et al. Nicotinic acetylcholine receptor distribution in Alzheimer s disease, dementia with Lewy bodies, Parkinson s disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a Neuropsychopharmacology 2004; 29: Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson s disease. Science 1997; 276: Hardy J. The relationship between Lewy body disease, Parkinson s disease, and Alzheimer s disease. Ann N Y Acad Sci 2003; 991: Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson s disease. Science 2003; 302: Tsuang DW, Dalan AM, Eugenio CJ, et al. Familial dementia with Lewy bodies: a clinical and neuropathological study of 2 families. Arch Neurol 2002; 59: Harding AJ, Das A, Kril JJ, Brooks WS, Duffy D, Halliday GM. Identification of families with cortical Lewy body disease. Am J Med Genet In press. 45. Singleton AB, Wharton A, O Brien KK, et al. Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2002; 14: Parsian A, Racette B, Goldsmith LJ, Perlmutter JS. Parkinson s disease and apolipoprotein E: possible association with dementia but not age at onset. Genomics 2002; 79: Dubois B, Pillon B. Cognitive deficits in Parkinson s disease. J Neurol 1997; 244: Ballard CG, Aarsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002; 59: Cormack F, Aarsland D, Ballard CG, Trovée MJ. Pentagon drawing and neuropsychological performance in dementia with Lewy bodies, Alzheimer s disease, Parkinson s disease and Parkinson s disease with dementia. Int J Geriatr Psychiatry 2004; 19: Ballard C, Holmes C, McKeith I, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer s disease. Am J Psychiatry 1999; 156: Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer s disease and Parkinson s disease comparison groups. Neurology 1996; 47: Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson s disease with and without dementia. Int J Geriatr Psychiatry 2001; 16: Boeve. Boeve F, Silber M, Ferman T. REM Sleep Behavior Disorder in Parkinson s Disease and Dementia With Lewy Bodies. J Geriatr Psychiatry Neurol 2004; 17: Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson s disease: a community-based study. Arch Neurol 1996; 53: Aarsland D, Ballard C, McKeith I, Perry RH, Larsen JP. Comparison of extrapyramidal signs in dementia with Lewy bodies and Parkinson s disease. J Neuropsychiatry Clin Neurosci 2001; 13: Gnanalingham KK, Byrne EJ, Thornton A, Sambrook MA, Bannister P. Motor and cognitive function in Lewy body dementia: comparison with Alzheimer s and Parkinson s diseases. J Neurol Neurosurg Psychiatry 1997; 62: Burn DJ, Rowan EN, Minett T, et al. Extrapyramidal features in Parkinson s disease with and without dementia and dementia with Lewy bodies: a cross-sectional comparative study. Mov Disord 2003; 18: Ballard C, O Brien J, Swann A, et al. One year follow-up of parkinsonism in dementia with Lewy bodies. Dement Geriatr Cogn Disord 2000; 11: Poewe WH, Wenning GK. The natural history of Parkinson s disease. Neurology 1996; 47:S146-S McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305: Aarsland D, Ballard CG, Larsen JP, McKeith IG, O Brien J, Perry R. Marked neuroleptic sensitivity in dementia with Lewy bodies and Parkinson s disease. Nord J Psychiatry 2003; 57: Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson s disease with dementia. Int J Geriatr Psychiatry 2003; 18: Molloy S, O Brien J, McKeith IG, Burn D. The motor response to levodopa (Ldopa) in dementia with Lewy bodies (DLB): a comparison to Parkinson s disease (PD) with and without

10 Parkinson s Disease and Dementia / Aarsland et al 145 dementia. Paper presented at: 3rd International Workshop on Dementia With Lewy Bodies and Parkinson s Disease Dementia (DLB/PDD); 2003; Newcastle Upon Tyne, United Kingdom. 64. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 60: Ballard CG, Jacoby R, Del Ser T, et al. Neuropathological substrates of psychiatric symptoms in autopsy-confirmed prospectively studied patients with dementia with Lewy bodies (DLB). Am J Psychiatry 2004; 161: Aarsland D, Litvan I, Salmon D, Galasko D, Wentzel-Larsen T, Larsen JP. Performance on the dementia rating scale in Parkinson s disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer s disease. J Neurol Neurosurg Psychiatry 2003; 74: Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y. Comparison of dementia with Lewy bodies to Alzheimer s disease and Parkinson s disease with dementia. Mov Disord 2004; 19: Horimoto Y, Matsumoto M, Nakazawa H, et al. Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson s disease with dementia. J Neurol Sci 2003; 216: Downes JJ, Priestley NM, Doran M, Ferran J, Ghadiali E, Cooper P. Intellectual, mnemonic, and frontal functions in dementia with Lewy bodies: a comparison with early and advanced Parkinson s disease. Behav Neurol 1998; 11: Cahn-Weiner DA, Williams K, Grace J, Tremont G, Westervelt H, Stern RA. Discrimination of dementia with Lewy bodies from Alzheimer disease and Parkinson disease using the clock drawing test. Cogn Behav Neurol 2003; 16: Burn DJ, McKeith IG. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson s disease. Mov Disord 2003; 18(suppl 6):S72-S Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson s disease versus dementia with Lewy bodies. J Clin Psychiatry 2002; 63: Rouleau I, Salmon DP, Butters N, et al. Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn. 1992; Jan;18: Bourke J, Castleden CM, Stephen R, Dennis M. Short report: a comparison of clock and pentagon drawing in Alzheimer's disease. Int J Geriatr Psychiatry. 1995;10: Stern Y, Mayeux R, Sano M, et al. Predictors of disease course in patients with probable Alzheimer's disease. Neurology. 1987;37:

T he prevalence of Parkinson s disease (PD) is nearly 1% in

T he prevalence of Parkinson s disease (PD) is nearly 1% in 708 PAPER Donepezil for cognitive impairment in Parkinson s disease: a randomised controlled study D Aarsland, K Laake, J P Larsen, C Janvin... See end of article for authors affiliations... Correspondence

More information

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia

The Spectrum of Lewy Body Disease: Dementia with Lewy Bodies and Parkinson's Disease Dementia Disclosures Research support, Parkinson Society Canada, Canadian Institutes of Health Research, Ministry of Economic Development and Innovation, Teva Novartis clinical trial, Principal Investigator CME

More information

Update on functional brain imaging in Movement Disorders

Update on functional brain imaging in Movement Disorders Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF

More information

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril

Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration

More information

Revised criteria for the clinical diagnosis of dementia with Lewy. Dementia with Lewy bodies. (Dementia with Lewy Bodies)

Revised criteria for the clinical diagnosis of dementia with Lewy. Dementia with Lewy bodies. (Dementia with Lewy Bodies) Dementia with Lewy bodies First described: Okazaki H, 1961, Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp

More information

Clinical Features and Treatment of Parkinson s Disease

Clinical Features and Treatment of Parkinson s Disease Clinical Features and Treatment of Parkinson s Disease Richard Camicioli, MD, FRCPC Cognitive and Movement Disorders Department of Medicine University of Alberta 1 Objectives To review the diagnosis and

More information

A prospective study of dementia with Lewy bodies

A prospective study of dementia with Lewy bodies Age and Ageing 998; 27: 6-66 998, British Geriatrics Society A prospective study of dementia with Lewy bodies CLIVE G. BALLARD, JOHN O'BRIEN, KATH LOWERX GARETH A. AYRE, RICHARD HARRISON, ROBERT PERRY,

More information

Lewy body disease (LBD) is the second most common

Lewy body disease (LBD) is the second most common REGULAR ARTICLES Lewy Body Disease: Can We Diagnose It? Michelle Papka, Ph.D. Ana Rubio, M.D., Ph.D. Randolph B. Schiffer, M.D. Christopher Cox, Ph.D. The authors assessed the accuracy of published clinical

More information

Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer s disease

Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer s disease J Neurol Neurosurg Psychiatry 2001;70:483 488 483 Center for Alzheimer Disease and Related Disorders, Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA

More information

Parkinsonian Disorders with Dementia

Parkinsonian Disorders with Dementia Parkinsonian Disorders with Dementia George Tadros Consultant in Old Age Liaison Psychiatry, RAID, Heartlands Hospital Professor of Dementia and Liaison Psychiatry, Aston Medical School Aston University

More information

ORIGINAL CONTRIBUTION. Diagnostic Accuracy of Dementia With Lewy Bodies. to be the second

ORIGINAL CONTRIBUTION. Diagnostic Accuracy of Dementia With Lewy Bodies. to be the second ORIGINAL CONTRIBUTION Diagnostic Accuracy of Dementia With Lewy Bodies Ursula Hohl, MD; Pietro Tiraboschi, MD; Lawrence A. Hansen, MD; Leon J. Thal, MD; Jody Corey-Bloom, MD, PhD Background: Diagnostic

More information

Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson s Disease

Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson s Disease Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson s Disease Dag Aarsland, M.D., Ph.D. Irene Litvan, M.D. Jan P. Larsen, M.D., Ph.D. Neuropsychiatric symptoms are common

More information

Nature, prevalence and clinical significance. Barcelona, Spain

Nature, prevalence and clinical significance. Barcelona, Spain Nature, prevalence and clinical significance Jaime Kulisevsky Barcelona, Spain 1 Non motor (neuropsychiatric) symptoms are an integral part of Parkinson s s disease (PD) Affective disorders And are associated

More information

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits

More information

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of

More information

Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University

Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview

More information

DEMENTIA IN PARKINSON`S DISEASE. DR C PADMAKUMAR MD FRACP FRCP(Edin) Director-Parkinson`s Disease Service for the Older Person HNELHD

DEMENTIA IN PARKINSON`S DISEASE. DR C PADMAKUMAR MD FRACP FRCP(Edin) Director-Parkinson`s Disease Service for the Older Person HNELHD DEMENTIA IN PARKINSON`S DISEASE DR C PADMAKUMAR MD FRACP FRCP(Edin) Director-Parkinson`s Disease Service for the Older Person HNELHD DEMENTIA IN PD The concept of Non Motor Symptoms in PD Dementia in Parkinson`s

More information

Dementia in Parkinson s disease:

Dementia in Parkinson s disease: Dementia in Parkinson s disease: A 20 year Prospective Neuropsychological Study Sydney Multicentre Study Associate Professor Wayne GJ Reid PhD FAPS 149 newly diagnosed community living Parkinson s Disease

More information

Range of neuropsychiatric disturbances in patients with Parkinson s disease

Range of neuropsychiatric disturbances in patients with Parkinson s disease 492 Section of Geriatric Psychiatry, Rogaland Psychiatric Hospital D Aarsland N G Lim C Janvin Department of Neurology, Central Hospital of Rogaland, Stavanger, Norway J P Larsen K Karlsen E Tandberg Departments

More information

Clinical features of dementia with lewy bodies in 35 Chinese patients

Clinical features of dementia with lewy bodies in 35 Chinese patients Han et al. Translational Neurodegeneration 2014, 3:1 Translational Neurodegeneration RESEARCH Open Access Clinical features of dementia with lewy bodies in 35 Chinese patients Ding Han, Qiong Wang, Zhongbao

More information

Neuropsychological profile of dementia with Lewy bodiespsy_283

Neuropsychological profile of dementia with Lewy bodiespsy_283 85..90 doi:10.1111/j.1479-8301.2009.00283.x PSYCHOGERIATRICS 2009; 9: 85 90 REVIEW ARTICLE Neuropsychological profile of dementia with Lewy bodiespsy_283 Haruhiko ODA, Yasuji YAMAMOTO and Kiyoshi MAEDA

More information

Dementia With Lewy Bodies: A Review Of Clinical Diagnosis, Neuropathology And Management Options Tanis J. Ferman, Ph.D.

Dementia With Lewy Bodies: A Review Of Clinical Diagnosis, Neuropathology And Management Options Tanis J. Ferman, Ph.D. Dementia With Lewy Bodies: A Review Of Clinical Diagnosis, Neuropathology And Management Options Tanis J. Ferman, Ph.D. Table 1. Core And Supportive Features For The Clinical Diagnosis Of DLB. 13 1. The

More information

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends

More information

Kurz MW, MD 1, 2, Larsen JP, MD, PhD 2, 3, Kvaloy JT, PhD 4, 5, Aarsland D, MD, PhD 2. Norway. Norway. Norway

Kurz MW, MD 1, 2, Larsen JP, MD, PhD 2, 3, Kvaloy JT, PhD 4, 5, Aarsland D, MD, PhD 2. Norway. Norway. Norway Paper V 1 Associations between family history of Parkinson s disease and dementia and risk of dementia in Parkinson s disease. A community-based, longitudinal study. Kurz MW, MD 1, 2, Larsen JP, MD, PhD

More information

ORIGINAL CONTRIBUTION. An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease

ORIGINAL CONTRIBUTION. An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease ORIGINAL CONTRIBUTION An Investigation of Clinical Correlates of Lewy Bodies in Autopsy-Proven Alzheimer Disease Yaakov Stern, PhD; Diane Jacobs, PhD; James Goldman, MD; Estrella Gomez-Tortosa, PhD; Bradley

More information

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA

Clinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal

More information

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language

More information

MOVEMENT DISORDERS AND DEMENTIA

MOVEMENT DISORDERS AND DEMENTIA MOVEMENT DISORDERS AND DEMENTIA FOCUS ON DEMENTIA WITH LEWY BODIES MADHAVI THOMAS MD NORTH TEXAS MOVEMENT DISORDERS INSTITUTE, INC DEMENTIA de men tia dəˈmen(t)sh(ē)ə/ nounmedicine noun: dementia a chronic

More information

DEMENS MED LEWYLEGEMER OG PARKINSON DEMENS

DEMENS MED LEWYLEGEMER OG PARKINSON DEMENS DEMENS MED LEWYLEGEMER OG PARKINSON DEMENS Dag Årsland Regionalt senter for eldremedisin og samhndling (SEAM), Stavanger Dept of Old age psychiatry, Institute of Psychiatry, Psychology and Neuroscience,

More information

ORIGINAL CONTRIBUTION. Dopamine Transporter Loss Visualized With FP-CIT SPECT in the Differential Diagnosis of Dementia With Lewy Bodies

ORIGINAL CONTRIBUTION. Dopamine Transporter Loss Visualized With FP-CIT SPECT in the Differential Diagnosis of Dementia With Lewy Bodies ORIGINAL CONTRIBUTION Dopamine Transporter Loss Visualized With FP-CIT SPECT in the Differential Diagnosis of Dementia With Lewy Bodies John T. O Brien, DM, MRCPysch; Sean Colloby, MPhil; John Fenwick,

More information

ORIGINAL CONTRIBUTION. Attention and Fluctuating Attention in Patients With Dementia With Lewy Bodies and Alzheimer Disease

ORIGINAL CONTRIBUTION. Attention and Fluctuating Attention in Patients With Dementia With Lewy Bodies and Alzheimer Disease ORIGINAL CONTRIBUTION Attention and Fluctuating Attention in Patients With Dementia With Lewy Bodies and Alzheimer Disease Clive Ballard, MRCPsych, MD; John O Brien, MRCPsych, DM; Alistair Gray, BSc; Franchesca

More information

10/30/2018. How do we diagnose dementia? Subtypes of dementia Case Studies

10/30/2018. How do we diagnose dementia? Subtypes of dementia Case Studies http://www.alz.org/alzheimers_disease_10_signs_of_alzheimers.asp#signs How do we diagnose dementia? Subtypes of dementia Case Studies 1. Memory loss that disrupts daily life Forgetting important dates

More information

C linicians have noted a close association between. Lewy body cortical involvement may not always predict dementia in Parkinson s disease PAPER

C linicians have noted a close association between. Lewy body cortical involvement may not always predict dementia in Parkinson s disease PAPER 852 PAPER Lewy body cortical involvement may not always predict dementia in Parkinson s disease C Colosimo, A J Hughes, L Kilford, A J Lees... See end of article for authors affiliations... Correspondence

More information

Original Articles. Calne, resting tremor. Mortimer, Pirozzolo, Hansch, & Webster, postural disturbance III

Original Articles. Calne, resting tremor. Mortimer, Pirozzolo, Hansch, & Webster, postural disturbance III 2004 97-106 Original Articles 1 2 3 1 1 2 3 47 22 III I II muscular rigidity postural disturbance resting tremor bradykinesia Calne, 2001 Mortimer, Pirozzolo, Hansch, & Webster, 1982 Tel: 02-23627076 E-mail:

More information

212 Index C-SB-13,

212 Index C-SB-13, Index A Acetylcholinesterase inhibitor, treatment, 15 Age-associated memory impairment (AAMI), 5 Alzheimer s disease (AD), 40, 95 96 apolipoprotein E genotype and risk for, 58 cellular neurodegeneration

More information

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018 Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been

More information

COGNITIVE IMPAIRMENT IN PARKINSON S DISEASE

COGNITIVE IMPAIRMENT IN PARKINSON S DISEASE 1 GENERAL INTRODUCTION GENERAL INTRODUCTION PARKINSON S DISEASE Parkinson s disease (PD) is a neurodegenerative movement disorder, named after James Parkinson who described some of its characteristic

More information

Non Alzheimer Dementias

Non Alzheimer Dementias Non Alzheimer Dementias Randolph B Schiffer Department of Neuropsychiatry and Behavioral Science Texas Tech University Health Sciences Center 9/11/2007 Statement of Financial Disclosure Randolph B Schiffer,,

More information

DIFFUSE LEWY BODY DISEASE (DLBD)

DIFFUSE LEWY BODY DISEASE (DLBD) CASE #2 Mr. S is a 62 years old male who was hospitalized in the dept. of psychogeriatrics after a suicide attempt (tried to jump from his balcony on the second floor). After a few days it was clear that

More information

Brain imaging for the diagnosis of people with suspected dementia

Brain imaging for the diagnosis of people with suspected dementia Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis

More information

Dementia. Assessing Brain Damage. Mental Status Examination

Dementia. Assessing Brain Damage. Mental Status Examination Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological

More information

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD

DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive

More information

FDG-PET e parkinsonismi

FDG-PET e parkinsonismi Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism

More information

Recent publications using the NACC Database. Lilah Besser

Recent publications using the NACC Database. Lilah Besser Recent publications using the NACC Database Lilah Besser Data requests and publications Using NACC data Number of requests by year Type 2009 2010 2011 2012 2013 2014 2015 Data files* 55 85 217 174 204

More information

Lewy Bodies in the Amygdala

Lewy Bodies in the Amygdala ORIGINAL CONTRIBUTION Lewy Bodies in the Amygdala Increase of -Synuclein Aggregates in Neurodegenerative Diseases With Tau-Based Inclusions Anca Popescu, MD; Carol F. Lippa, MD; Virginia M.-Y. Lee, PhD;

More information

Basal ganglia motor circuit

Basal ganglia motor circuit Parkinson s Disease Basal ganglia motor circuit 1 Direct pathway (gas pedal) 2 Indirect pathway (brake) To release or augment the tonic inhibition of GPi on thalamus Direct pathway There is a tonic inhibition

More information

Neuropsychological Evaluation of

Neuropsychological Evaluation of Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish

More information

Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy- Confirmed Dementia With Lewy Bodies

Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy- Confirmed Dementia With Lewy Bodies Article Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy- Confirmed Dementia With Lewy Bodies Clive G. Ballard, M.R.C.Psych., M.D. Robin Jacoby, F.R.C.Psych.,

More information

Cognitive-Motor Interference in Persons with Parkinson Disease

Cognitive-Motor Interference in Persons with Parkinson Disease Cognitive-Motor Interference in Persons with Parkinson Disease Tara L. McIsaac, PhD, PT Associate Professor of Physical Therapy A.T. Still University Arizona School of Health Sciences October 11, 2014

More information

Imaging biomarkers for Parkinson s disease

Imaging biomarkers for Parkinson s disease 3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 6 MDS-ES/EAN: Neuroimaging in movement disorders - Level 2 Imaging biomarkers for Parkinson

More information

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:

More information

ORIGINAL CONTRIBUTION. Comparison of Clinical Manifestations in Alzheimer Disease and Dementia With Lewy Bodies

ORIGINAL CONTRIBUTION. Comparison of Clinical Manifestations in Alzheimer Disease and Dementia With Lewy Bodies ORIGINAL CONTRIBUTION Comparison of Clinical Manifestations in Alzheimer Disease and Dementia With Lewy Bodies Angela Nervi, MD; Christiane Reitz, MD, PhD; Ming-Xin Tang, PhD; Vincent Santana, MBA; Angel

More information

Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer s Disease

Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer s Disease Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of Alzheimer s Disease Debby Tsuang, MD, MSc, Kate Simpson, MPH, Eric B. Larson, MD, MPH, Elaine Peskind, MD, Walter Kukull,

More information

Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer s disease

Frontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer s disease International Psychogeriatrics: page 1 of 8 C 2009 International Psychogeriatric Association doi:10.1017/s1041610209009454 Frontotemporal dementia and dementia with Lewy bodies in a case-control study

More information

Differential Diagnosis of Alzheimer s Disease and Other Types of Dementia with Development of Neuroimaging Techniques (PET, SPECT, and MRI)

Differential Diagnosis of Alzheimer s Disease and Other Types of Dementia with Development of Neuroimaging Techniques (PET, SPECT, and MRI) www.jmscr.igmpublication.org Impact Factor 1.1147 ISSN (e)-2347-176x Differential Diagnosis of Alzheimer s Disease and Other Types of Dementia with Development of Neuroimaging Techniques (PET, SPECT, and

More information

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit Objectives RAIN Difficult Diagnosis 2014: A 75 year old woman with falls Alexandra Nelson MD, PhD UCSF Memory and Aging Center/Gladstone Institute of Neurological Disease Recognize important clinical features

More information

ORIGINAL CONTRIBUTION. The Progression of Cognition, Psychiatric Symptoms, and Functional Abilities in Dementia With Lewy Bodies and Alzheimer Disease

ORIGINAL CONTRIBUTION. The Progression of Cognition, Psychiatric Symptoms, and Functional Abilities in Dementia With Lewy Bodies and Alzheimer Disease ORIGINAL CONTRIBUTION The Progression of Cognition, Psychiatric Symptoms, and Functional Abilities in Dementia With Lewy Bodies and Alzheimer Disease Karina Stavitsky, BS; Adam M. Brickman, PhD; Nikolaos

More information

Introduction. Clinical manifestations

Introduction. Clinical manifestations Dementia in Parkinson disease Martin R Farlow MD ( Dr. Farlow of Indiana University received research grant support from AbbVie, Accera, Biogen, Eisai, Eli Lilly, Genentech, Roche, Lundbeck, Novartis,

More information

Neuropsychiatric disturbances such as delusions,

Neuropsychiatric disturbances such as delusions, Differential Neuropsychiatric Responses to Tacrine in Alzheimer s Disease: Relationship to Dementia Severity Daniel Kaufer, M.D. Jeffrey L. Cummings, M.D. Dianne Christine, R.N. Neuropsychiatric symptom

More information

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes

More information

Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical

Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical 161Journal of Neurology, Neurosurgery, and Psychiatry 1997;62:16-21 Alzheimer's Treatment and Research Center, Department of Neurology, Ramsey Clinic/Health- Partners, University of Minnesota, St Paul,

More information

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN

DIFFERENTIAL DIAGNOSIS SARAH MARRINAN Parkinson s Academy Registrar Masterclass Sheffield DIFFERENTIAL DIAGNOSIS SARAH MARRINAN 17 th September 2014 Objectives Importance of age in diagnosis Diagnostic challenges Brain Bank criteria Differential

More information

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function

More information

Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment (MCI) October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine

More information

Delirium & Dementia. Nicholas J. Silvestri, MD

Delirium & Dementia. Nicholas J. Silvestri, MD Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts

More information

Neuro degenerative PET image from FDG, amyloid to Tau

Neuro degenerative PET image from FDG, amyloid to Tau Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging

More information

Synaptic changes in dementia: links to cognition and behaviour

Synaptic changes in dementia: links to cognition and behaviour Synaptic changes in dementia: links to cognition and behaviour Paul T Francis, PhD Professor of Neurochemistry Director, Brains for Dementia Research Agenda Discuss synaptic changes in various dementias

More information

7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER FOURTEEN CHAPTER OUTLINE. Dementia, Delirium, and Amnestic Disorders. Oltmanns and Emery

7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER FOURTEEN CHAPTER OUTLINE. Dementia, Delirium, and Amnestic Disorders. Oltmanns and Emery ABNORMAL PSYCHOLOGY SEVENTH EDITION Oltmanns and Emery PowerPoint Presentations Prepared by: Ashlea R. Smith, Ph.D. This multimedia and its contents are protected under copyright law. The following are

More information

III./3.1. Movement disorders with akinetic rigid symptoms

III./3.1. Movement disorders with akinetic rigid symptoms III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.

More information

ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey

ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact

More information

UDS version 3 Summary of major changes to UDS form packets

UDS version 3 Summary of major changes to UDS form packets UDS version 3 Summary of major changes to UDS form packets from version 2 to VERSION 3 february 18 final Form A1: Subject demographics Updated question on principal referral source to add additional options

More information

Mild cognitive impairment in Parkinson s disease: a distinct clinical entity?

Mild cognitive impairment in Parkinson s disease: a distinct clinical entity? Wen et al. Translational Neurodegeneration (2017) 6:24 DOI 10.1186/s40035-017-0094-4 REVIEW Mild cognitive impairment in Parkinson s disease: a distinct clinical entity? Ming-Ching Wen 1,2*, Ling Ling

More information

NIH Public Access Author Manuscript Mov Disord. Author manuscript; available in PMC 2009 May 18.

NIH Public Access Author Manuscript Mov Disord. Author manuscript; available in PMC 2009 May 18. NIH Public Access Author Manuscript Published in final edited form as: Mov Disord. 2008 August 15; 23(11): 1602 1605. doi:10.1002/mds.22161. Emergence of Parkinsons Disease in Essential Tremor: A Study

More information

Visual Hallucinations in Dementia: A Prospective Community-Based Study With Autopsy

Visual Hallucinations in Dementia: A Prospective Community-Based Study With Autopsy Visual Hallucinations in Dementia: A Prospective Community-Based Study With Autopsy Debby Tsuang, M.D., M.Sc., Eric B. Larson, M.D., M.P.H., Elizabeth Bolen, B.S., Mary Lou Thompson, Ph.D., Elaine Peskind,

More information

The ABCs of Dementia Diagnosis

The ABCs of Dementia Diagnosis The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What

More information

Dementia in Parkinson's Disease: A Clinical Review

Dementia in Parkinson's Disease: A Clinical Review American Journal of Neuroscience 2 (1): 35-47, 2011 ISSN 1948-9900 2011 Science Publications Dementia in Parkinson's Disease: A Clinical Review 1 Renata Teles Vieira, 1 Leonardo Caixeta, 2,3 Sergio Machado

More information

Role of Neuropsychiatric Assessment in Diagnosis and Research

Role of Neuropsychiatric Assessment in Diagnosis and Research Role of Neuropsychiatric Assessment 163 11 Role of Neuropsychiatric Assessment in Diagnosis and Research Dag Aarsland, Uwe Ehrt, and Clive Ballard INTRODUCTION Although the basal ganglia have traditionally

More information

Parkinson's diseases. dementia: companson with Alzheimer's and. Motor and cognitive function in Lewy body. of patients with Lewy body dementia

Parkinson's diseases. dementia: companson with Alzheimer's and. Motor and cognitive function in Lewy body. of patients with Lewy body dementia J7ournal of Neurology, Neurosurgery, and Psychiatry 1997;62:243-252 Department of Old Age Psychiatry K K Gnanalingham E Byrne A Thornton Department of Neurology, Withington Hospital, Nell lane, West Didsbury,

More information

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci.

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci. How to Diagnose Early (Prodromal) Lewy Body Dementia Ian McKeith MD, FRCPsych, F Med Sci. Parkinson s Disease Lewy Body Disease Time PD Dementia Lewy Body Dementias Dementia with Lewy Bodies (DLB) Diagnostic

More information

Evaluation of Parkinson s Patients and Primary Care Providers

Evaluation of Parkinson s Patients and Primary Care Providers Evaluation of Parkinson s Patients and Primary Care Providers 2018 Movement Disorders Half Day Symposium Elise Anderson MD Medical Co-Director, PBSI Movement Disorders 6/28/2018 1 Disclosures GE Speaker,

More information

ORIGINAL ARTICLE. Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease

ORIGINAL ARTICLE. Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease ORIGINAL ARTICLE Early and Widespread Cholinergic Losses Differentiate Dementia With Lewy Bodies From Alzheimer Disease Pietro Tiraboschi, MD; Larry A. Hansen, MD; Michael Alford, BA; Annette Merdes, MD;

More information

Clinical presentation and differential diagnosis of dementia with Lewy bodies: a review

Clinical presentation and differential diagnosis of dementia with Lewy bodies: a review REVIEW ARTICLE Clinical presentation and differential diagnosis of dementia with Lewy bodies: a review L. F. Morra and P. J. Donovick State University of New York at Binghamton, Binghamton, NY, USA Correspondence

More information

Regulatory Challenges across Dementia Subtypes European View

Regulatory Challenges across Dementia Subtypes European View Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions

More information

Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.

Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease

More information

Dementia with Lewy Bodies. A Distinct Non-Alzheimer Dementia Syndrome?

Dementia with Lewy Bodies. A Distinct Non-Alzheimer Dementia Syndrome? Brain Pathology 8: 299-324(1998) Dementia with Lewy Bodies. A Distinct Non-Alzheimer Dementia Syndrome? Paul G. Ince 1, 2, Elaine K. Perry 1, Chris. M. Morris 1 MRC Neurochemical Pathology Unit 1, University

More information

Dementia and Healthy Ageing : is the pathology any different?

Dementia and Healthy Ageing : is the pathology any different? Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association

More information

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that

More information

Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation

Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation 1. Reflection of Mild Cognitive Impairment (MCI) and Dementias by Molecular Imaging, PET

More information

Behavioral Aspects of Parkinson s Disease

Behavioral Aspects of Parkinson s Disease Behavioral Aspects of Parkinson s Disease Joseph H. Friedman, MD Director, Movement Disorders Program Butler Hospital Dept of Neurology Alpert Medical School of Brown University 1 Disclosures Drugs will

More information

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe A. J. Harding, 1 G. A. Broe 1 and G. M. Halliday 1 Brain (2002), 125, 391±403 1 Prince of Wales Medical Research Institute

More information

Dementia is a common neuropsychiatric disorder characterized by progressive impairment of

Dementia is a common neuropsychiatric disorder characterized by progressive impairment of Focused Issue of This Month Diagnosis and Treatment for Behavioral and Psychological Symptoms of Dementia Byoung Hoon Oh, MD Department of Psychiatry, Yonsei University College of Medicine E - mail : drobh@yuhs.ac

More information

Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases

Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer

More information

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:

More information

Early and Presenting Symptoms of Dementia with Lewy Bodies

Early and Presenting Symptoms of Dementia with Lewy Bodies Original Research Article DOI: 10.1159/000333072 Accepted: September 6, 2011 Published online: November 16, 2011 Early and Presenting Symptoms of Dementia with Lewy Bodies Eirik Auning a Arvid Rongve c

More information

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease

More information

Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16

Diagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16 The impact of FDG PET in degenerative dementia diagnosis Jung Lung, Hsu MD, Ph.D (Utrecht) Section of dementia and cognitive impairment Department of Neurology Chang Gung Memorial Hospital, Linkou, Taipei

More information

A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies

A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies Lynda Mackin, PhD, AGPCNP-BC, CNS University of California San Francisco School of Nursing 1 Alzheimer s

More information

Parkinson e decadimento cognitivo. Stelvio Sestini

Parkinson e decadimento cognitivo. Stelvio Sestini Parkinson e decadimento cognitivo Stelvio Sestini Patients with PD can develop a spectrum of cognitive symptoms Heterogeneity of cognitive deficits The cognitive symptoms can evolve to dementia (Mov Disorder

More information